Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3568 - Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France. Final results of the AVANTAGE study.


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research



Tumour Site


Falchero Lionel


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


F. Lionel1, D. Perol2, P. Souquet3, H. Le Caer4, E. Dansin5, C. Audigier Valette6, J. Mouysset7, M.L. Uffredi8, M. Ionescu-Goga9, K. Veerabudun10, Y. Lelarge11, E. Fabre-Guillevin12

Author affiliations

  • 1 Service De Pneumologie Et Cancérologie Thoracique, L'Hopital Nord Ouest, 69655 cedex - Villefranche Sur Saone/FR
  • 2 69, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Service De Pneumologie Et Cancérologie Thoracique, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 4 Pneumologie, Centre Hospitalier, 22000 - Saint Brieuc/FR
  • 5 Service De Pneumologie, Centre Oscar Lambret, 59020 - Lille/FR
  • 6 Service De Pneumologie, Hospital Sainte Musse, 83100 - Toulon/FR
  • 7 Medical Oncology, Clinique Rambot-Provençale, 13100 - Aix-en-Provence/FR
  • 8 Medical, Roche S.A.S., 92650 - Boulogne-Billancourt/FR
  • 9 Pharmaco-vigilance, Roche S.A.S., 92650 - Boulaogne-billancourt/FR
  • 10 Statistics, aixial, 92100 - boulogne-billancourt/FR
  • 11 Operation Clinique, Hays, 75008 - Paris/FR
  • 12 Service De Pneumologie, Dr. Elizabeth Fabre-Guillevin, La Défense/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3568


NSCLC is frequent in elderly patients (pts), however there is limited information on the treatment of this population. This study describes the first-line treatment with bevacizumab (bev) of NSCLC elderly pts in real life in France.


AVANTAGE is a non-interventional, prospective, multicenter French study conducted in pts with advanced NSCLC starting first-line chemotherapy (CT) with bev. It includes 2 cohorts, pts aged 65-70 (C1), or ≥ 70 (C2) . Data were collected at inclusion and every 3 months subsequently for 18 months. The primary objective was to describe CT used with bev in first-line in routine clinical practice.


A total of 249 pts were eligible (277 included) in 68 centers: 108 (43%) in C1 & 141 (57%) in C2. They were predominantly men (75%), ECOG PS 0-1 (85%) PS 2 (15%), G8 questionnaire score >14 (35%), stage IV (96%), Charlson comorbidity index unadjusted ≤2 (63%), and brain metastases identified in 18% of pts overall, 20% of pts in C2. Platinum-based doublet CT and pemetrexed (pem) was the most used combination with bev in 186 (75%) pts overall: - 81% of pts in C1 (62% cisplatin-pem and 18% carboplatin-pem) - 70% of pts in C2 (26% cisplatin-pem and 44% carboplatin-pem). The initial dose of bev with CT was 7.5 mg/kg/3 weeks in 70% of pts. Overall, maintenance treatment was administered to 61% pts, including 53% with bev (24% in monotherapy and 29% with pem). Maintenance was 64% in C1and 62% in C2. Median PFS was 7.1 months, and median OS was 12.3 months (14.9 months in C1, 11.3 months in C2). Overall, 92% of pts presented at least 1 AE. Pts with grade ≥ 3 AEs related to bev were 12% in C1 and 24% in C2. In the safety population (260), 148 pts died during the study. 3 pts (all in C2) died due to SAEs related to treatment (intestinal perforation; febrile neutropenia/septic shock/ thrombocytopenia; unknown cause).


AVANTAGE is the 1st prospective cohort conducted in routine clinical practice in France in elderly pts eligible for 1st-line CT with bev. The most frequently used treatment was the combination of platinum-pem doublet (75% of pts). Bev effectiveness as 1st line treatment in NSCLC was consistent with the efficacy observed in clinical trials in the elderly as was the safety profile.

Clinical trial identification

Clincial Trial Gov: NCT01893268.

Legal entity responsible for the study

Roche S.A.S.


Roche S.A.S.

Editorial Acknowledgement

Dr Samia Rahal from ELTIUM (French medical writting company).


F. Lionel, D. Perol, H. Le Caer, P-J. Souquet: Payment for advisory: Roche. E. Dansin: Payment for advisory: Roche, Lilly, MSD. C. Audigier Valette: Payment for advisory: Roche, Pfizer, Boehringer Ingelheim, Lilly, AstraZeneca, Amgen, Bristol-Myers Squibb, Symex, MSD, Clovis Oncology, Novartis. J.-L. Mouysset, E. Fabre-Guillevin: Payment as study's investigator: Roche. M.L. Uffredi, M. Ionescu-Goga: Employee: Roche. K. Veerabudun, Y. Lelarge: Business partner employee: Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.